Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Aft on Identifying Markers for Micrometastatic Disease

July 24th 2013

Rebecca L. Aft, MD, PhD, from the Siteman Cancer Center, discusses the need to identify markers for patients with micrometastatic disease.

BOLERO-3: Everolimus Might Help Patients Overcome Trastuzumab Resistance

July 23rd 2013

Adding the mTOR inhibitor everolimus to conventional therapy slowed the progression of trastuzumab-resistant advanced breast cancer, and in the process, provided clues to the origin of trastuzumab resistance.

Dr. Minetta Liu on CTCs for Prognosis and Prediction

July 23rd 2013

Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, discusses the use of circulating tumor cells (CTCs) for prognosis and prediction in patients with breast cancer.

Dr. Lehman on Breast Imaging Across Cancer Centers

July 22nd 2013

Constance D. Lehman, MD, PhD, from the Seattle Cancer Care Alliance, discusses breast imaging across various cancer centers.

Adding Paclitaxel to Neratinib Improves Outcomes Versus Monotherapy

July 22nd 2013

Combining paclitaxel with the investigational compound neratinib increased response rates versus neratinib alone in patients with HER2-positive metastatic breast cancer.

Dr. Mittendorf on Peptide Vaccines for Breast Cancer

July 19th 2013

Elizabeth Mittendorf, MD, PhD, from MD Anderson Cancer Center, discusses the use of peptide vaccines for the treatment of breast cancer.

Suzanne A. W. Fuqua, PhD, on the Androgen Receptor

July 18th 2013

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the androgen receptor in breast cancer.

Dr. Seidman Discusses Less Lymph Node Surgery

July 11th 2013

Andrew D. Seidman, MD, from Weill Cornell Cancer Center and Memorial Sloan-Kettering Cancer Center, discusses less surgery for patients with breast cancer.

Retrospective Analysis Confirms Poor Prognosis for Breast Cancer Patients With BRCA1 Mutations

July 11th 2013

Women with breast cancer who are carriers of BRCA1 mutations have increased mortality compared with noncarriers, according to a retrospective study carried out in the Netherlands.

Dr. Garcia on a Trial Analyzing the PARP Inhibitor Veliparib

July 8th 2013

Agustin A. Garcia, MD, from the Keck School of Medicine of the University of Southern California, discusses a phase I trial analyzing the PARP inhibitor veliparib (ABT-888) in patients with breast cancer.

Hypofractionation Emerges as Standard, but Not Yet for Every Patient

July 8th 2013

Recently published clinical trial results support new radiation therapy protocols for many breast cancer survivorsâŽ¯protocols that could greatly improve collective outcome.

Priority Review Granted to Neoadjuvant Breast Cancer Regimen

July 2nd 2013

The FDA has granted priority review to a regimen of pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive early-stage breast cancer.

Dr. Budd Discusses Paclitaxel Regimens in Breast Cancer

June 25th 2013

G. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, discusses the background and results of the S0221 trial in breast cancer.

Ellen Matloff on the Supreme Court Gene Patenting Decision

June 25th 2013

Ellen T. Matloff, MS, CGC, from the Yale School of Medicine/Yale Cancer Center, describes the impact of the US Supreme Court decision to restrict the patenting of segments of DNA in isolation.

Amount of HER2 Expression Associated With Response to T-DM1 in HER2-Positive Metastatic Breast Cancer

June 21st 2013

Women with the highest expression of HER2 had the most benefit from T-DM1, while the presence of PIK3CA mutations had no effect on response to T-DM1 but did interfere with response to capecitabine/lapatinib.

Dr. Hudis on the CALGB 40601 Study in Breast Cancer

June 20th 2013

Clifford A. Hudis, MD, chief of the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center in New York, discusses the findings of the CALGB 40601 study in breast cancer.

Lack of Discontinuation of Statin Therapy After Diagnosis of End-Stage Cancer

June 14th 2013

The diagnosis of end-stage cancer rarely led to the clinically indicated discontinuation of statin therapy when prescribed for primary prevention.

Dr. O'Shaughnessy on Eribulin in Metastatic Breast Cancer

June 14th 2013

Joyce A. O'Shaughnessy, MD, from the Baylor Charles A. Sammons Cancer Center, reviews findings from Study 301, which compared eribulin mesylate to capecitabine for patients with locally advanced or metastatic breast cancer.

Dr. Aft on Disseminating Tumor Cells and Prognosis

June 14th 2013

Rebecca L. Aft, MD, PhD, discusses the identification of patients with breast cancer at high risk of recurrent disease development by detection of HER2-positive disseminated tumor cells in bone marrow of patients with HER2-negative tumors.

Supreme Court Limits Ability to Patent Genes in Landmark Decision

June 13th 2013

After years of varying decisions by lower courts regarding the patents held on a test for genetic mutations associated with breast cancer, the US Supreme Court has ruled that a segment of DNA in isolation is a natural product and not eligible for patent protection.